Statistical recommendations for count, binary, and ordinal data in rare disease cross-over trials

Author:

Geroldinger MartinORCID,Verbeeck Johan,Hooker Andrew C.,Thiel Konstantin E.,Molenberghs Geert,Nyberg Joakim,Bauer Johann,Laimer Martin,Wally Verena,Bathke Arne C.,Zimmermann Georg

Abstract

Abstract Background Recommendations for statistical methods in rare disease trials are scarce, especially for cross-over designs. As a result various state-of-the-art methodologies were compared as neutrally as possible using an illustrative data set from epidermolysis bullosa research to build recommendations for count, binary, and ordinal outcome variables. For this purpose, parametric (model averaging), semiparametric (generalized estimating equations type [GEE-like]) and nonparametric (generalized pairwise comparisons [GPC] and a marginal model implemented in the R package nparLD) methods were chosen by an international consortium of statisticians. Results It was found that there is no uniformly best method for the aforementioned types of outcome variables, but in particular situations, there are methods that perform better than others. Especially if maximizing power is the primary goal, the prioritized unmatched GPC method was able to achieve particularly good results, besides being appropriate for prioritizing clinically relevant time points. Model averaging led to favorable results in some scenarios especially within the binary outcome setting and, like the GEE-like semiparametric method, also allows for considering period and carry-over effects properly. Inference based on the nonparametric marginal model was able to achieve high power, especially in the ordinal outcome scenario, despite small sample sizes due to separate testing of treatment periods, and is suitable when longitudinal and interaction effects have to be considered. Conclusion Overall, a balance has to be found between achieving high power, accounting for cross-over, period, or carry-over effects, and prioritizing clinically relevant time points.

Funder

H2020 Societal Challenges

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Genetics (clinical),General Medicine

Reference36 articles.

1. Aoki Y, Röshammar D, Hamrén B, Hooker AC. Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection. J Pharmacokinet Pharmacodyn. 2017;44(6):581–97. https://doi.org/10.1007/s10928-017-9550-0.

2. Ast (n.d.) ASTERIX: advances in small trials design for regulatory innovation and excellence. FP7-HEALTH-2013-INNOVATION-1 Grant-Agreement No. 603160. https://www.asterix-fp7.eu/

3. Bartlett MS. Properties of sufficiency and statistical tests. Proc R Soc Lond Ser A Math Phys Sci. 1937;160(901):268–82.

4. Brunner E, Bathke AC, Konietschke F. Rank and pseudo-rank procedures for independent observations in factorial designs, using R and SAS. Berlin Heidelberg: Springer; 2019.

5. Brunner E, Munzel U. Nichtparametrische Datenanalyse: Unverbundene Stichproben. Berlin, Heidelberg: Springer; 2013.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Medical Statistics in Drug Development and Regulatory Approval;Advances in Bioinformatics and Biomedical Engineering;2024-07-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3